Evommune, Inc.

TRex Bio Inc. (TRexBio) announced an $84m series B venture capital round on 13 November that it will use to develop lead drug candidate TRB-061, a TNFR2 agonist, through early clinical proof-of-concep

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. ProGen Partners With Rani To Devel

Two new venture capital funds based outside of the US together offer $365m for life science start-ups, including Amplitude Ventures’ second fund and XGEN Venture’s inaugural fund. Montreal-based Ampli

Incyte Corporation sees potential in Escient Pharmaceuticals Inc. ’s MRGPR X2 and X4 antagonists to augment ongoing programs in its pipeline and to begin generating revenue at about the same time th